In 2017, the FDA launched its Digital Health Action Plan with legislation specifically targeting digital health, in which it intends to harness the potential of digital health in a conscientious manner. In this second session, our guest experts will present an overview of the regulatory landscape and the challenges related to privacy and data protection. They will also address the future of reimbursement for digital health products.
- Sally Bowden, COO, Renalytix AI
- Melissa Hudzik, Senior Counsel, Regulatory
- Vernessa Pollard, Partner, McDermott Will & Emery
- Lisa Placanica, Senior Managing Director, Center for Technology Licensing at Weill Cornell Medicine (WCM)
More information on Weill Digital Health Series: